TRIB - トリニティ・バイオテック （Trinity Biotech plc） トリニティ・バイオテックTRIBのチャート
TRIBの企業情報
| symbol | TRIB |
|---|---|
| 会社名 | Trinity Biotech Plc （トリニティ・バイオテック） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: In Vitro_In Vivo Diagnostic Substances |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 トリニティー・バイオテック(Trinity Biotech plc)は診断市場における臨床検査室とポイントオブケア(POC)区分向けの医療診断用製品の開発・買収・製造・販売に従事する。同社が提供した製品は自己免疫疾患、伝染病、性的感染症、糖尿病、及び血液、肝臓、腸の疾患などの検出に使用される。また、同社は子会社Fitzgerald Industriesを通じて世界中の生命科学産業及び研究所に原材料を提供する。同社は世界における75ヵ国の顧客に275種を超える製品を販売する。同社は国内・国際代理販売店のネットワークを通して、又は直接に米国及び世界における他の国家・地区で製品を販売する。平成23年1月に、同社はPhoenix Bio-tech Corporationの100％株式を買収した。平成24年3月に、同社はFiomi Diagnostics ABの100％株式を買収した。 トリニティ・バイオテックはアイルランドで医療診断製品を開発、製造、販売。臨床検査室とポイントオブケア(診療室やベットサイドでの検査)に自己免疫疾患、感染症、性感染症、糖尿病、肝臓・腸疾患の診断製品を提供。HIV検査キット、トロポニン検査キット、ウイルス性呼吸器感染キットなどをおよそ100カ国で販売。 Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. |
| 本社所在地 | IDA Business Park Bray Co. Wicklow IRL |
| 代表者氏名 | Ronan O'Caoimh ロナン・オカオイム |
| 代表者役職名 | Executive Chairman of the Board 取締役会長 |
| 電話番号 | +353 1-276-9800 |
| 設立年月日 | 33604 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 1992年 |
| 従業員数 | 556人 |
| url | www.trinitybiotech.com |
| nasdaq_url | https://www.nasdaq.com/symbol/trib |
| adr_tso | 23955575 |
| EBITDA | EBITDA（百万ドル） 4.47900 |
| 終値（lastsale） | 3.93 |
| 時価総額（marketcap） | 94145409.75 |
| 時価総額 | 時価総額（百万ドル） 94.71998 |
| 売上高 | 売上高（百万ドル） 98.95700 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 140.47298 |
| 当期純利益 | 当期純利益（百万ドル） -39.08400 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Trinity Biotech plc (ADR) revenues decreased less than 1% to $48.8M. Net income decreased 55% to $972K. Revenues reflect market conditions. Net income was partially offset by Non-cash financial (expense) / income decrease from $1.2M (income) to $354K (expense) Indirect share based payments increase from $380K to $763K (expense) Research and development expenses increase of 2% to $2.7M (expense). |
TRIBのテクニカル分析
TRIBのニュース
Trinity Biotech plc (TRIB) CEO Ronan O''Caoimh on Q1 2022 Results - Earnings Call Transcript 2022/06/30 19:43:03 Seeking Alpha
Trinity Biotech plc (NASDAQ:NASDAQ:TRIB) Q1 2022 Earnings Conference Call June 30, 2022, 11:00 AM ET Company Participants Joe Diaz - Lytham Partners, IR Ronan O’Caoimh - Chairman and Chief…
Trinity Biotech GAAP EPADS of -50c, revenue of $18.78M misses by $1.22M 2022/06/30 13:14:35 Seeking Alpha
Trinity Biotech press release (TRIB): Q1 GAAP EPADS of -50c.Revenue of $18.78M (-26.6% Y/Y) misses by $1.22M.
Trinity Biotech Announces Quarter 1 2022 Financial Results 2022/06/30 13:07:00 GlobeNewswire
DUBLIN, Ireland, June 30, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company’s results for the quarter ended March 31, 2022.
Trinity Biotech plc to Announce First Quarter Fiscal Year 2022 Financial Results 2022/06/29 21:20:00 GlobeNewswire
Conference Call Scheduled for June 30, 2022 at 11:00 am EASTERN Conference Call Scheduled for June 30, 2022 at 11:00 am EASTERN
Trinity biotech receives European approval for rapid COVID-19 antigen test 2022/05/20 15:54:01 Seeking Alpha
Trinity Biotech (TRIB) said on Friday it had achieved the European CE Mark or approval for its 10-minute Covid-19 antigen test. This CE mark allows for use by healthcare professionals…
Trinity Biotech Plc - ADR Shares Close in on 52-Week Low - Market Mover 2022/01/09 10:42:45 Kwhen Finance
Trinity Biotech Plc - ADR (TRIB) shares closed today at 0.8% above its 52 week low of $1.30, giving the company a market cap of $27M. The stock is currently down 8.4% year-to-date, down 67.2% over the past 12 months, and down 80.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 73.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 3.0% The company's stock price performance over the past 12 months lags the peer average by 511.1%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Trinity Biotech Plc - ADR Shares Fall 5.1% Below Previous 52-Week Low - Market Mover 2022/01/08 04:21:45 Kwhen Finance
Trinity Biotech Plc - ADR (TRIB) shares closed 5.1% lower than its previous 52 week low, giving the company a market cap of $28M. The stock is currently down 3.5% year-to-date, down 67.9% over the past 12 months, and down 79.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.7%. Trading Activity Trading volume this week was 73.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 6.1% lower than its 5-day moving average, 14.9% lower than its 20-day moving average, and 33.9% lower than its 90-day moving average.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -49.2% The company's stock price performance over the past 12 months lags the peer average by 750.1%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Trinity Biotech (NASDAQ:TRIB) Downgraded to D- at TheStreet 2021/12/24 06:44:42 Dakota Financial News
TheStreet downgraded shares of Trinity Biotech (NASDAQ:TRIB) from a c- rating to a d- rating in a report published on Monday, TheStreetRatingsTable reports. TRIB stock opened at $1.58 on Monday. The companys 50-day simple moving average is $1.88 and its 200 day simple moving average is $2.26. Trinity Biotech has a 52 week low of []
Trinity Biotech Announces Q3 2021 Results, the Entry Into a $81,250,000 Loan Facility to Refinance the Companys Exchangeable Senior Notes and Agreements To Repurchase Outstanding Exchangeable Senior Notes 2021/12/15 23:21:00 Intrado Digital Media
DUBLIN, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the Company), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended September 30, 2021, the entry into a $81.25million loan facility to refinance the existing $99.9million of exchangeable senior notes issued by the Companys subsidiary, Trinity Biotech Investment Limited (the Notes), and exchange agreements for over 99.7% of the outstanding Notes, all subject to certain conditions precedent.
Global Point of care Diagnostics Market Size [2021-2028] | to Reach USD 36.21 Billion by 2028 2021/12/07 08:52:00 Intrado Digital Media
Key Players Covered in the Point of Care Diagnostics Market Research Report Are F. Hoffmann-La Roche Ltd (Basel, Switzerland), Thermo Fisher Scientific Inc. (Massachusetts, U.S.), Abbott Laboratories (Illinois, U.S), Quest Diagnostics Incorporated (New Jersey, United States), BD (Franklin Lakes, U.S), bioMérieux SA (Marcy l''Etoile, France), Cardinal Health, Inc. (Ohio, U.S), Mesa Biotech (California, U.S), Cepheid (California, U.S), Trinity Biotech (Bray, Ireland), Quidel Corporation (San Diego, U.S.), Bio-Rad Laboratories Inc. (California, U.S) and other key market players Key Players Covered in the Point of Care Diagnostics Market Research Report Are F. Hoffmann-La Roche Ltd (Basel, Switzerland), Thermo Fisher Scientific Inc. (Massachusetts, U.S.), Abbott Laboratories (Illinois, U.S), Quest Diagnostics Incorporated (New Jersey, United States), BD (Franklin Lakes, U.S), bioMérieux SA (Marcy l''Etoile, France), Cardinal Health, Inc. (Ohio, U.S), Mesa Biotech (California, U.S), Cepheid (California, U.
Trinity Biotech Plc - ADR Shares Close in on 52-Week Low - Market Mover 2022/01/09 10:42:45 Kwhen Finance
Trinity Biotech Plc - ADR (TRIB) shares closed today at 0.8% above its 52 week low of $1.30, giving the company a market cap of $27M. The stock is currently down 8.4% year-to-date, down 67.2% over the past 12 months, and down 80.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 73.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 3.0% The company's stock price performance over the past 12 months lags the peer average by 511.1%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Trinity Biotech Plc - ADR Shares Fall 5.1% Below Previous 52-Week Low - Market Mover 2022/01/08 04:21:45 Kwhen Finance
Trinity Biotech Plc - ADR (TRIB) shares closed 5.1% lower than its previous 52 week low, giving the company a market cap of $28M. The stock is currently down 3.5% year-to-date, down 67.9% over the past 12 months, and down 79.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.7%. Trading Activity Trading volume this week was 73.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 6.1% lower than its 5-day moving average, 14.9% lower than its 20-day moving average, and 33.9% lower than its 90-day moving average.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -49.2% The company's stock price performance over the past 12 months lags the peer average by 750.1%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Trinity Biotech (NASDAQ:TRIB) Downgraded to D- at TheStreet 2021/12/24 06:44:42 Dakota Financial News
TheStreet downgraded shares of Trinity Biotech (NASDAQ:TRIB) from a c- rating to a d- rating in a report published on Monday, TheStreetRatingsTable reports. TRIB stock opened at $1.58 on Monday. The companys 50-day simple moving average is $1.88 and its 200 day simple moving average is $2.26. Trinity Biotech has a 52 week low of []
Trinity Biotech Announces Q3 2021 Results, the Entry Into a $81,250,000 Loan Facility to Refinance the Companys Exchangeable Senior Notes and Agreements To Repurchase Outstanding Exchangeable Senior Notes 2021/12/15 23:21:00 Intrado Digital Media
DUBLIN, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the Company), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended September 30, 2021, the entry into a $81.25million loan facility to refinance the existing $99.9million of exchangeable senior notes issued by the Companys subsidiary, Trinity Biotech Investment Limited (the Notes), and exchange agreements for over 99.7% of the outstanding Notes, all subject to certain conditions precedent.
Global Point of care Diagnostics Market Size [2021-2028] | to Reach USD 36.21 Billion by 2028 2021/12/07 08:52:00 Intrado Digital Media
Key Players Covered in the Point of Care Diagnostics Market Research Report Are F. Hoffmann-La Roche Ltd (Basel, Switzerland), Thermo Fisher Scientific Inc. (Massachusetts, U.S.), Abbott Laboratories (Illinois, U.S), Quest Diagnostics Incorporated (New Jersey, United States), BD (Franklin Lakes, U.S), bioMérieux SA (Marcy l''Etoile, France), Cardinal Health, Inc. (Ohio, U.S), Mesa Biotech (California, U.S), Cepheid (California, U.S), Trinity Biotech (Bray, Ireland), Quidel Corporation (San Diego, U.S.), Bio-Rad Laboratories Inc. (California, U.S) and other key market players Key Players Covered in the Point of Care Diagnostics Market Research Report Are F. Hoffmann-La Roche Ltd (Basel, Switzerland), Thermo Fisher Scientific Inc. (Massachusetts, U.S.), Abbott Laboratories (Illinois, U.S), Quest Diagnostics Incorporated (New Jersey, United States), BD (Franklin Lakes, U.S), bioMérieux SA (Marcy l''Etoile, France), Cardinal Health, Inc. (Ohio, U.S), Mesa Biotech (California, U.S), Cepheid (California, U.